<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01525823</url>
  </required_header>
  <id_info>
    <org_study_id>CA191-015</org_study_id>
    <nct_id>NCT01525823</nct_id>
  </id_info>
  <brief_title>Assessment of Blood Glucose Changes in Healthy Volunteers After BMS-754807 Alone or BMS-754807 With Metformin</brief_title>
  <acronym>NHV</acronym>
  <official_title>Effects of Metformin on Glucose Homeostasis Following Administration of BMS-754807 in Healthy Volunteer Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effects of Metformin administered over two weeks
      on the peak plasma glucose concentrations following administration of BMS-754807.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Purpose: Other - Protocol designed to evaluate pharmacodynamics following
      administration of two compounds
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean difference of the peak plasma glucose concentrations following administration of BMS-754807 alone and following 2 weeks of Metformin administration</measure>
    <time_frame>On Day 3 and Day 17</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety endpoints: AEs and marked clinical laboratory abnormalities</measure>
    <time_frame>Day -21 to Day 47</time_frame>
    <description>Incidence of adverse events (AEs), AEs leading to discontinuation, serious adverse events (SAEs), and deaths occurring up to 30 days after the last dose of study medication and marked abnormalities of laboratory values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BMS-754807 and M5</measure>
    <time_frame>9 timepoints over 24 hours following Day 1 dose and 12 timepoints over 72 hours for the Day 5 dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of BMS-754807 and M5</measure>
    <time_frame>9 timepoints over 24 hours following Day 1 dose and 12 timepoints over 72 hours for the Day 5 dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-754807 and M5</measure>
    <time_frame>12 timepoints over 72 hours for the Day 5 dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve in one dosing interval [AUC(TAU)] of BMS-754807 and M5</measure>
    <time_frame>9 timepoints over 24 hours following Day 1 dose and 12 timepoints over 72 hours for the Day 5 dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to the last quantifiable plasma concentration [AUC(0-T)] of BMS-754807 and M5</measure>
    <time_frame>9 timepoints over 24 hours following Day 1 dose and 12 timepoints over 72 hours for the Day 5 dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma half-life (T-HALF) of BMS-754807 and M5</measure>
    <time_frame>12 timepoints over 72 hours for the Day 5 dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation index; ratio of AUC(TAU) at steady-state to AUC(TAU) after the first dose (AI) of BMS-754807 and M5</measure>
    <time_frame>9 timepoints over 24 hours following Day 1 dose and 12 timepoints over 72 hours for the Day 5 dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean levels of plasma glucose, serum insulin and c-peptide</measure>
    <time_frame>Day 3, Day 5 and Day 17</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>BMS-754807 + Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-754807 (IGR-IR/IR Inhibitor)</intervention_name>
    <description>Tablets, Oral, 100mg, Once daily, Days 1 - 5 and 15 - 17</description>
    <arm_group_label>BMS-754807 + Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Tablets, Oral, (1000mg on Days 3 - 9) and (2000mg on Days 10 - 17), Once daily</description>
    <arm_group_label>BMS-754807 + Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects ages 18 to 55 determined with no clinically
             significant deviation from normal medical history, physical examination,
             electrocardiograms (ECGs), and clinical laboratory

          -  Women who are not of childbearing potential

        Exclusion Criteria:

          -  Evidence of organ dysfunction or any clinically significant deviation from normal in
             physical examination, vital signs, ECG or clinical laboratory determinations
             consistent with a healthy volunteer target population

          -  History of clinically relevant hypoglycemic events

          -  History of clinically relevant hyperglycemic events
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol_Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2012</study_first_submitted>
  <study_first_submitted_qc>February 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2012</study_first_posted>
  <last_update_submitted>June 13, 2012</last_update_submitted>
  <last_update_submitted_qc>June 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

